--- title: "Tango reports 82% tumor response rate for combination therapy in advanced pancreatic cancer" description: "The figure is lower than the 92% the company reported in June, and it comes from a larger group of patients." url: https://lifestyle-health.skoop.news/tango-builds-on-revolution-medicines-8217-pancreatic-cancer--4d6941/ published: 2026-10-24T04:04:22.430037-04:00 modified: 2026-10-24T04:04:22.430056-04:00 section: "Lifestyle & Health" publisher: "skoop.news" language: en keywords: ["Tango", "Breakthrough Therapy Designation", "Malte Peters", "FDA", "MTAP", "PDAC"] hashtags: ["#BreakthroughTherapyDesignation", "#MaltePeters", "#Tango", "#lifestyle", "#wellness"] image: https://upload.wikimedia.org/wikipedia/commons/5/5b/MTAP_Secondary_Subunit_Structure.jpg?utm_source=commons.wikimedia.org&utm_campaign=imageinfo&utm_content=thumbnail_unscaled --- # Tango reports 82% tumor response rate for combination therapy in advanced pancreatic cancer > The figure is lower than the 92% the company reported in June, and it comes from a larger group of patients. Published 2026-10-24 · Updated 2026-10-24 · Lifestyle & Health, [skoop.news](https://skoop.news/) ## In brief - Tango reports an 82% tumor response rate for its trial of a combination therapy in advanced pancreatic cancer, a result that matters to people living with the disease and their families [[1]](https://www.statnews.com/2026/10/23/tango-pancreatic-cancer-star-moderna-readout-newsletter/). - The 82% response rate is a drop from the 92% response rate Tango reported in June, which came from fewer patients [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). - Dose level 2, which used 250 mg vopimetostat and 600 mg daraxonrasib, was not well tolerated [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## The finding Tango reports an 82% tumor response rate for its trial of a combination therapy in advanced pancreatic cancer, a result that matters to people living with the disease and their families [[1]](https://www.statnews.com/2026/10/23/tango-pancreatic-cancer-star-moderna-readout-newsletter/). The combination pairs vopimetostat with daraxonrasib [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). CEO Malte Peters said the response rate and durability of the combination surpass any published PDAC datasets, even in front-line settings [[3]](https://www.tikr.com/blog/tango-therapeutics-sinks-13-on-pancreatic-cancer-data-it-says-surpass-any-published-pdac-datasets?ref=yahoofinance). PDAC is pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. ## Why the number changed The 82% response rate is a drop from the 92% response rate Tango reported in June, which came from fewer patients [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). In June, the company reported data from 12 patients showing a 92% response rate and 90% progression-free survival at six months [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). Progression-free survival is the share of patients whose cancer has not grown at a set time point. The new figure comes from a larger group, so the two numbers are not drawn from the same pool of patients [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## Dosing results Dose level 2, which used 250 mg vopimetostat and 600 mg daraxonrasib, was not well tolerated [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). Three of four patients at that level experienced dose-limiting toxicities, meaning side effects serious enough to limit the dose [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## The drug behind the combination The FDA approved daraxonrasib, as Rasonque, for second-line pancreatic cancer [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). In September, weeks after that approval, the agency granted Breakthrough Therapy Designation to daraxonrasib in the first-line setting [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## What Tango plans next Tango plans to launch a Phase 3 trial of the combination in front-line pancreatic cancer patients with MTAP deletions in the first half of 2027 [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). Approximately 40% of patients with pancreatic cancer have an MTAP deletion [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). The company also plans to seek FDA guidance on a possible accelerated approval path for vopimetostat plus daraxonrasib in second-line pancreatic cancer [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). A Friday SEC filing says Tango is deprioritizing novel target discovery [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## What it means for you If you or a family member has pancreatic cancer, the MTAP deletion is the detail to watch, because Tango's planned Phase 3 trial is aimed at front-line patients with that deletion [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). About 40% of patients with pancreatic cancer have one [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). Daraxonrasib is already FDA approved, as Rasonque, for second-line pancreatic cancer [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). The combination with vopimetostat is not approved, and Tango plans to ask the FDA about a possible accelerated approval path in the second-line setting [[2]](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3). ## Sources 1. [Tango builds on Revolution Medicines’ pancreatic cancer success](https://www.statnews.com/2026/10/23/tango-pancreatic-cancer-star-moderna-readout-newsletter/) — STAT 2. [ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3](https://www.biospace.com/drug-development/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phase-3) — BioSpace 3. [Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”](https://www.tikr.com/blog/tango-therapeutics-sinks-13-on-pancreatic-cancer-data-it-says-surpass-any-published-pdac-datasets?ref=yahoofinance) — Yahoo Finance Image: Photo: Hstuhlma / Wikimedia Commons, CC BY-SA 4.0 (https://commons.wikimedia.org/wiki/File:MTAP_Secondary_Subunit_Structure.jpg) --- Written from the sources above and checked twice (rules and an independent model) before publishing. How we work: https://skoop.news/how-we-work/ · Corrections: https://skoop.news/corrections/